GlassScriptPhysician profile
Samuel Schwarz
NPI 1699855452
$2,832.68
in general payments reported to CMS, 2019-2025
15 companies · $648 in 2025
The $648 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $215 · 2021: $539 · 2022: $419 · 2023: $464 · 2024: $267 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $823.33 | 2019-2025 | Xifaxan |
| Abbvie INC. | $513.43 | 2021-2025 | Linzess, Viberzi |
| Madrigal Pharmaceuticals | $448.52 | 2024-2025 | Rezdiffra |
| Novo Nordisk INC | $167.75 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $142.28 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $134.64 | 2023 | Zeposia |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Cook Medical LLC | $120.55 | 2025 | Rosen |
| Horizon Therapeutics Plc | $97.06 | 2022 | |
| Ardelyx, INC. | $61.59 | 2024-2025 | Ibsrela |
| Medtronic, INC. | $60.10 | 2023 | Endurant Iis |
| Glaxosmithkline, LLC. | $48.13 | 2021 | |
| Daiichi Sankyo INC. | $41.50 | 2020-2021 | |
| Boston Scientific Corporation | $37.93 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Schwarz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.